Informations:
Erreur:
Mots-clés
SKF104864A ×
- Clinical Trial (19)
- AML (13)
- Myelodysplastic Syndromes (13)
- Lung Neoplasms (11)
- Medical Oncology (10)
- Laboratories (8)
- Adverse event (7)
- Small Cell Lung Carcinoma (6)
- Clinical Trial, Phase III (5)
- Carcinoma (5)
- Cisplatin (5)
- Carcinoma, Non-Small-Cell Lung (4)
- Concomitant Medication (4)
- Trial screening (4)
- Hematology (3)
- Rectal Neoplasms (2)
- Urinalysis (2)
- Toxicity Tests (2)
- Body Surface Area (2)
- Body Weight (2)
- Chemistry, Clinical (2)
- Vital Signs (2)
- Drug trial (2)
- Electrocardiography (2)
- Ovarian Neoplasms (2)
- Physical Examination (1)
- Quality of Life (1)
- Radiotherapy (1)
- Sarcoma (1)
- Drugs, Investigational (1)
- Sex Cord-Gonadal Stromal Tumors (1)
- Blood Transfusion (1)
- Clinical Chemistry Tests (1)
- Lost to Follow-Up (1)
- Drug-Related Side Effects and Adverse Reactions (1)
- Specimen (1)
- Disease Response (1)
- End of Study (1)
- Electrocardiogram (ECG) (1)
- Non Small Cell Lung Cancer (1)
- Demography (1)
- Eligibility Determination (1)
- Etoposide (1)
- Follow-Up Studies (1)
- Giant Cell Tumors (1)
- Gynecology (1)
- Histology (1)
- Medical History Taking (1)
- Anti-Bacterial Agents (1)
- Neoplasms (1)
- Neoplasms by Site (1)
Table des matières
Modèles de données sélectionnés
Vous devez être connecté pour sélectionner plusieurs modèles de données, les télécharger ou les analyser.
32 Résultats de recherche.
Groupes Item: Identification Numbers, Serious Adverse Experience (SAE) , Additional Informations
Groupes Item: Identification Numbers, Supportive Therapy Transfusion, If Yes to Supportive Therapy (Including Erythropoietin), Supportive Anti-Infective Therapy, If Yes to Supportive Anti-Infective Therapy, Concominant Medication
Groupes Item: Identification Numbers, Adverse Experiences (non-Serious), Adverse Experiences (non-Serious)
Groupes Item: Identification Numbers, Response Assessment at the end of the Course, Study Status, Best Overall Response Assessment, Study Conclusion, Investigator`s Signature
Groupes Item: Identification Numbers, Serious Adverse Experiences, 12-Lead Electrocardiogram, Echocardiogram or Multiple Gated Acquisition Scanning (MUGA), If Yes for the obtained Ejection Fraction, Chest X-Ray
Groupes Item: Identification Numbers, Demography, Vital Signs, 12-Lead Electrocardiogram, Echocardiogram or Multiple Gated Acquisition Scanning (MUGA), If Yes for the obtained Ejection Fraction, Chest X-Ray, History of Myelodysplastic Syndrome / Acute Myelogenous Leukemia, Previous Chemotherapy for MDS or AML, If Yes to Previous Chemotherapy for MDS or AML, Previous Biologic Therapy and/or Immunotherapy for MDS or AML, If Yes to Previous Biologic Therapy and/or Immunotherapy for MDS or AML, Toxicities Related to Previous Therapy for MDS or AML, If Yes to Toxicities Related to Previous Therapy for MDS or AML, Prior Transfusion Therapy (Including Erythropoietin), If Yes to Prior Transfusion Therapy (Including Erythropoietin), Prior Anti-Infective Therapy, If Yes to Prior Anti-Infective Therapy, Prior and Concominant Medication, If Yes to Prior and Concominant Medication, Ongoing Medical Conditions Associated with MDS or AML, If Yes to Ongoing Medical Conditions Associated with MDS or AML, Prior Malignancies, If Yes to Prior Malignancies, Significant Medical/Surgery History and Physical Examination, If Yes to Significant Medical/Surgery History and Physical Examination
Groupes Item: Identification Numbers, Topotecan and Ara-C Study Medication Record, Topotecan Administration, Ara-C Administration, Idarubicin and Ara-C Study Medication Record, Idarubicin Administration, Ara-C Administration, G-CSF Study Medication Record, Vital Signs-TAG Regiment only, Vital Signs-IDAG Regiment only
Groupes Item: Identification Numbers, Inclusion Criteria, Exclusion Criteria, Telephone Randomisation, If Yes to Telephone Randomisation